In its 16th annual report, the Resource Tracking for HIV Prevention Research & Development Working Group documents research and development spending for the calendar year 2020 and analyzes funding trends spanning twenty years.
hivresourcetracking.org
The most up-to-date and comprehensive field-wide estimates for HIV prevention and R&D globally.
Pregnant and Lactating People (PLP) in Ongoing HIV Prevention Trials
Lessons Learned for Delivery PrEP Implementation
Current trends for investment in HIV prevention R&D by technology
Px Wire February 2023
Volume 13, Number 1
This issue offers data from Q4 of 2022, when South Africa became the fourth country in the world to approve injectable cabotegravir (CAB) for PrEP; the dapivirine vaginal ring (DVR) was approved in a growing number of countries; and oral PrEP use was on the rise, passing the mark of 3.8 million initiations. For the first time, the world has multiple biomedical interventions to offer choice, and it’s essential to develop the programs that bring the fruits of science to the communities facing public health threats, while continuing to invest in developing new options to meet diverse needs.
Advancing HIV Prevention Research in Pregnant and Lactating People (PLP): Think Tank Report & Action Plan
The work of the AVAC/PHASES think tank to advance HIV prevention research with pregnant and lactating people was importantly grounded in a trio of conceptual frameworks: 1. Reproductive Justice, 2. Conceptual shifts articulated in the Pregnancy and HIV/AIDS: Seeking Equitable Study (PHASES) Ethics Guidance and 3. WHO/ IMPAACT framework for accelerated inclusion of pregnant women in pre-licensure clinical trials.
Faster, Smarter and More Equitable – Accelerating Roll Out and Uptake of CAB for PrEP
Monday, August 8, 2022
As we begin rolling out injectable cabotegravir (CAB) as PrEP, what lessons have we learned from the first 10 years of oral PrEP implementation? How can we do better with a new PrEP intervention that offers new opportunities and distinct challenges? Learn more in this Choice Agenda webinar.
Featuring Rachel Baggaley, Caroline Carnevale, Monica Gandhi and Mitchell Warren
More than Vessels: Pregnant people deserve inclusion in HIV prevention clinical and implementation research
Wednesday, December 14, 2022
During this webinar, panelists explored the need for Pregnant and Lactating Populations (PLP) to be included HIV prevention clinical and implementation research
Speakers included Dr. Elaine Abrams, Raniyah Copeland, Dr. Lisa Noguchi and Dr. Lynda Stranix-Chibanda. The discussion was moderated by Dr. Dvora Joseph Davey.
Status Updates on Ongoing and Planned HIV Prevention Trials
The world is grappling with the far-reaching impacts of the COVID-19 pandemic and the HIV prevention field is no different. Most trials investigating new biomedical HIV prevention products have paused, citing concerns for the safety of trial participants and the study teams.
How COVID-19 is impacting research varies by trial and site, and efforts are ongoing to minimize impact on trial timelines and data. AVAC will continue to monitor developments—watch this space.
COVID-19 Resources for Advocates
This document is to help advocates with links to the latest information about COVID-19, including information on its prevention, transmission, relationship to HIV and research that’s underway. Many of the links below are constantly updated so please click through for the latest.